CD87, a Prognostic and Diagnostic Flow Cytometry Marker in Myelodysplastic Syndrome
BJ Tierno, BD McMillen, DS Xu, L Loseph. Boston Medical Center, Boston, MA; CBL Pathology Laboratories, Rye Brook, NY
Background: We have previously demonstrated the maturing myeloid population in bone marrow shows loss of CD87 (urokinase plasminogen activator receptor) expression in myelodysplastic syndrome (MDS). In the current study, we assessed the potential role of CD87 as a prognostic tool.
Design: We performed a retrospective chart review of 28 patients who had a flow cytometry panel performed for the diagnosis of MDS between 2006 and 2008. The panel assessed myeloid cells for surface expression of CD13, CD16, CD10, CD87, HLADR and CD34. All patients had at least one of the following: positive flow cytometry for MDS, positive cytogenetics, and/or evidence of MDS on bone marrow biopsy. A retrospective chart review was performed and the hematocrit (HCT), white blood cell count (WBC) and platelet count (PLT) at patient presentation were obtained. We correlated the expression of CD10, in addition to CD87, with the HCT, WBC and PLT counts given that decreased CD10 expression is currently a more widely accepted marker for MDS.
Results: Of the 28 patients (14 male vs. 14 female, mean age 65, range 27-81), 18 had a decreased expression of CD87 (30). This group of patients had a significantly lower HCT and WBC when compared to the 10 patients with normal expression of CD87. The patients with a decreased CD87 had a average HCT of 25.2% 6.3 versus 31.5% 6.8 in the patients with normal CD87 expression (p=0.02). The decreased CD87 group also had a lower WBC the group with normal CD87 (3.3 K/uL 1.4vs. 6.2 K/uL 4.4, p=0.008). There was no significant difference in the platelet values (163 K/uL vs. 118 K/uL, p=0.35) between patients with decreased and normal CD87. The comparison of the 24 patients with decreased CD10 expression (30) and the four patients with normal CD10 expression did not show any significant differences in the HCT, WBC or PLT counts.
Conclusions: Loss of CD87 expression is not only useful for the diagnosis of MDS using flow cytometry, it is also associated with more severe anemia and leukopenia at clinical presentation. Expression of CD10, a more widely used flow cytometric marker in the diagnosis of MDS, showed no correlation with HCT, WBC and PLT counts. Additional prospective studies of CD87 and other flow cytometry markers are necessary to further elucidate the prognostic implications of loss of CD87, as well as other aberrantly expressed surface markers in MDS.
Monday, March 9, 2009 9:30 AM
Poster Session I Stowell-Orbison/Autopsy Award # 226, Monday Morning